Claims for Patent: 5,667,969

Summary for Patent: 5,667,969

Title:	Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
Abstract:	Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.
Inventor(s):	Sullenger; Bruce A. (Westminster, CO), Cech; Thomas R. (Boulder, CO)
Assignee:	University Research Corporation (Boulder, CO)
Application Number:	08/152,450
Patent Claims:	1. Method for splicing a non-viral target nucleic acid molecule within a cell in culture with a separate nucleic acid molecule, wherein said target molecule is deleterious to the cell in which it is located, and wherein said separate nucleic acid molecule is adapted to form a non-deleterious target molecule when spliced with at least a part of said target nucleic acid molecule, comprising the step of: contacting said target nucleic acid molecule with a catalytic nucleic acid molecule comprising said separate nucleic acid molecule under conditions in which at least a portion of said separate nucleic acid molecule is spliced with at least a portion of said target nucleic acid molecule to form said non-deleterious nucleic acid molecule. 2. The method of claim 1, wherein said catalytic nucleic acid molecule is active to cleave said target nucleic acid molecule and to splice said separate nucleic acid molecule with said target nucleic acid molecule. 3. The method of claim 1, wherein said catalytic nucleic acid molecule is a group I or group II intron molecule. 4. The method of claim 1, wherein said contacting is in vitro. 5. The method of claim 1, wherein said target nucleic acid is an RNA molecule. 6. The method of claim 1, wherein said separate nucleic acid molecule is an RNA molecule. 7. The method of claim 1, wherein said contacting comprises providing a vector encoding said catalytic nucleic acid molecule comprising said separate nucleic acid molecule.

Details for Patent 5,667,969

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26